Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic c...

Full description

Bibliographic Details
Published in:	Journal of Contemporary Medicine
Main Authors:	Ahmet Dirican, Gonca Akdere Ateş, Atike Pinar Erdoğan, Ferhat Ekinci, Özge Kama Başcı
Format:	Article
Language:	English
Published:	Rabia Yılmaz 2022-11-01
Subjects:	enzalutamid prostat kanseri böbrek yetmezliği enzalutamide prostate cancer renal failure
Online Access:	https://dergipark.org.tr/tr/download/article-file/2653132

Similar Items

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
by: Sung Hee Lim, et al.
Published: (2024-03-01)

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
by: Aswini Kumar, et al.
Published: (2023-01-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Integrated bioinformatics analysis reveals that OPRK1 inhibits ferroptosis and induces enzalutamide resistance in prostate cancer
by: Liangrong Zhang, et al.
Published: (2025-04-01)

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
by: Zhu Wen, et al.
Published: (2024-08-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
by: Stefanie Fischer, et al.
Published: (2020-01-01)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
by: Xu Wen, et al.
Published: (2023-05-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
by: Phoebe A. Tsao, et al.
Published: (2023-08-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity
by: Nicolas Malaquin, et al.
Published: (2020-07-01)

Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer
by: Yuanfa Feng, et al.
Published: (2023-03-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
by: Francesca Fiorentino, et al.
Published: (2023-04-01)

Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway
by: Hui-Yu Dong, et al.
Published: (2023-01-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
by: Thomson A, et al.
Published: (2024-10-01)

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review
by: Zineddine Belabaci, et al.
Published: (2025-05-01)

A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer
by: Jun Liu, et al.
Published: (2019-11-01)

Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer
by: Fu-Hao Ji, et al.
Published: (2025-08-01)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
by: Ralph E. White, et al.
Published: (2023-06-01)

Repurposing piroxicam enhances the antineoplastic effects of docetaxel and enzalutamide in prostate cancer cells using 2D and 3D in vitro culture models
by: Amani Yehya, et al.
Published: (2025-07-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
by: Günel Huseynova, et al.
Published: (2022-12-01)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
by: Jason Hu, et al.
Published: (2022-11-01)

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
by: Rebecka Hellsten, et al.
Published: (2022-10-01)

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Tomas Pokrivcak, et al.
Published: (2024-04-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
by: Yoshiyuki Miyazawa, et al.
Published: (2021-07-01)

Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer
by: Shiv Verma, et al.
Published: (2020-11-01)

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial
by: Landon C. Brown, et al.
Published: (2025-11-01)